TEST:

Oncomine™ Myeloid MRD Assays

We have demonstrated that the addition of SNAQ-SEQ IS spike-in standards produced expected VAF in response to dilution, and for AML samples, provided a direct per sample 0.3% VAF sensitivity QC. The IS variants replace the need for an external positive reference run control sample, enabling an additional patient sample to be run to increase testing throughput, flow cell utilization, and reduced testing cost. Second, the ability to compare the known versus measured IS VAF conveys the reporting accuracy of the test on a per-sample basis.

The user-friendly workflow and integrated informatics pipeline offer opportunities for streamlined testing and interpretation of results. The Ion Torrent Myeloid MRD DNA assay is a powerful new tool for MRD detection across a growing myeloid disease target landscape.

"Thermo Fisher Scientific...launched a next-generation sequencing (NGS)-based assay for research in myeloid measurable residual disease (MRD). As the first NGS-based tests to support both DNA and RNA input, the Ion Torrent Oncomine Myeloid MRD Assays (RUO) provide a comprehensive and highly sensitive MRD assessment from blood and bone marrow samples."